Sorafenib has been approved for liver cancer and kidney cancer [9], and has also shown therapeutic efficacy in acute myeloid leukemia (AML) patients with FLT3-ITD mutations, leading to improved patient survival [10]. The gene discussed is FLT3; the disease is acute myeloid leukemia.